Castellano takes Chief Financial Officer role at Abzena
Transatlantic bio company Abzena, an end-to-end integrated CDMO for complex biologic molecules and Antibody Drug Conjugates (ADCs) has appointed Thomas Castellano as Chief Financial Officer.
Abzena, whose global headquarters is at Babraham Research Campus in Cambridge UK, last year opened a new biologics testing laboratory close to its Biologics process development and manufacturing hub in San Diego.
Based in the US, Castellano is a leader in the CDMO industry, with more than 20 years of experience in corporate finance and capital markets, underpinned by a strong foundation in biotechnology industry finance.
He joins Abzena from Catalent, where he spent 15 years in financial leadership roles of increasing responsibility, most recently as the company’s Senior Vice President & Chief Financial Officer.
Matt Stober, CEO of Abzena said: “I am pleased to welcome Tom to the strong leadership team here at Abzena. Tom’s wealth and breadth of industry relevant financial experience will be valuable as we continue to build on our excellence in bioconjugation and biologics services.
Castellano added: “To join Abzena at this stage of the company’s growth provides me with an exciting opportunity. I am delighted to apply my deep experience in the CDMO industry to Abzena, who are moving medicine forward for the benefit of both customers and patients. I look forward to partnering with the leadership team on this new and exciting journey.”
Abzena secured an additional $65 million funding at the end of March 2022. Backers in the raise included majority owner Welsh, Carson, Anderson & Stowe (WCAS), Biospring Partners and other affiliated investors.